
SNTI Stock Forecast & Price Target
SNTI Analyst Ratings
Bulls say
Senti Biosciences is a clinical-stage biotechnology company developing cell and gene therapies for patients with incurable diseases. With promising results from its lead candidate, SENTI-202, in a Phase 1 clinical trial for relapsed/refractory AML and recently receiving RMAT designation, the company is well-positioned for future success. However, potential cash runway issues and anticipated dilution remain as concerns to be addressed.
Bears say
Senti Biosciences is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. The company has a novel gene circuit platform that is designed to reprogram cells to sense, compute, and respond to cellular environments. However, there are several key risks to the company's success, including the potential for unanticipated toxicities in its clinical trials, competition from other players in the cell therapy space, and potential manufacturing challenges. These risks could impact the company's ability to achieve its target sales and lead to downward revisions in its valuation. In addition, the company has a limited cash runway and may need to raise additional capital, leading to potential shareholder dilution. Therefore, as a financial analyst, I have a negative outlook on Senti Biosciences's stock.
This aggregate rating is based on analysts' research of Senti Biosciences Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
SNTI Analyst Forecast & Price Prediction
Start investing in SNTI
Order type
Buy in
Order amount
Est. shares
0 shares